A stable human p53 heterotetramer based on constructive charge interactions within the tetramerization domain

被引:15
作者
Brokx, RD [1 ]
Bolewska-Pedyczak, E [1 ]
Gariépy, J [1 ]
机构
[1] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada
关键词
D O I
10.1074/jbc.M208528200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The human p53 tetramerization domain (called p53tet; residues 325-355) spontaneously forms a dimer of dimers in solution. Hydrophobic interactions play a major role in stabilizing the p53 tetramer. However, the distinctive arrangement of charged residues at the dimer-dimer interface suggests that they also contribute to tetramer stability. Charge-reversal mutations at positions 343,346, and 351 within the dimer-dimer interface were thus introduced into p53tet constructs and shown to result in the selective formation of a stable heterotetramer composed of homodimers. More precisely, mutants p53tet-E343K/E346K and p53tet-K351E preferentially associated with each other, but not with wild-type p53tet, to form a heterodimeric tetramer with enhanced thermal stability relative to either of the two components in isolation. The p53tet-E343K/E346K mutant alone assembled into a weakly stable tetramer in solution, whereas p53tet-K351E existed only as a dimer. Moreover, these mutants did not form heterocomplexes with wild-type p53tet, illustrating the specificity of the ionic interactions that form the novel heterotetramer. This study demonstrates the dramatic importance of ionic interactions in altering the stability of the p53 tetramer and in selectively creating heterotetramers of this protein scaffold.
引用
收藏
页码:2327 / 2332
页数:6
相关论文
共 36 条
[1]  
Arrowsmith CH, 1996, ONCOGENE, V12, P1379
[2]   Multiple roles of the tumor suppressor p53 [J].
Bargonetti, J ;
Manfredi, JJ .
CURRENT OPINION IN ONCOLOGY, 2002, 14 (01) :86-91
[3]   p53 mutants without a functional tetramerisation domain are not oncogenic [J].
Chène, P ;
Bechter, E .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 286 (05) :1269-1274
[4]   The role of tetramerization in p53 function [J].
Chène, P .
ONCOGENE, 2001, 20 (21) :2611-2617
[5]   REFINED SOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF THE TUMOR-SUPPRESSOR P53 [J].
CLORE, GM ;
ERNST, J ;
CLUBB, R ;
OMICHINSKI, JG ;
KENNEDY, WMP ;
SAKAGUCHI, K ;
APPELLA, E ;
GRONENBORN, AM .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (04) :321-333
[6]   p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53 [J].
Davison, TS ;
Vagner, C ;
Kaghad, M ;
Ayed, A ;
Caput, D ;
Arrowsmith, CH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (26) :18709-18714
[7]   Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome [J].
Davison, TS ;
Yin, P ;
Nie, E ;
Kay, C ;
Arrowsmith, CH .
ONCOGENE, 1998, 17 (05) :651-656
[8]   Structure and functionality of a designed p53 dimer [J].
Davison, TS ;
Nie, X ;
Ma, WL ;
Lin, YP ;
Kay, C ;
Benchimol, S ;
Arrowsmith, CH .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 307 (02) :605-617
[9]   RAINBOW-TROUT P53 - CDNA CLONING AND BIOCHEMICAL-CHARACTERIZATION [J].
DEFROMENTEL, CC ;
PAKDEL, F ;
CHAPUS, A ;
BANEY, C ;
MAY, P ;
SOUSSI, T .
GENE, 1992, 112 (02) :241-245
[10]   A novel mechanism of tumorigenesis involving pH- dependent destabilization of a mutant p53 tetramer [J].
DiGiammarino, EL ;
Lee, AS ;
Cadwell, C ;
Zhang, WX ;
Bothner, B ;
Ribeiro, RC ;
Zambetti, G ;
Kriwacki, RW .
NATURE STRUCTURAL BIOLOGY, 2002, 9 (01) :12-16